Free Trial

Colgate-Palmolive (CL) Stock Forecast & Price Target

$98.07
+0.31 (+0.32%)
(As of 07/12/2024 ET)

Colgate-Palmolive - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$95.33
-2.79% Downside
High Forecast$112.00
Average Forecast$95.33
Low Forecast$76.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
7 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$95.33$92.94$88.56$84.75
Forecasted Upside-2.79% Downside9.02% Upside10.64% Upside12.89% Upside
Get Colgate-Palmolive Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CL and its competitors with MarketBeat's FREE daily newsletter.

CL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Colgate-Palmolive Stock vs. The Competition

TypeColgate-PalmoliveConsumer Staples CompaniesS&P 500
Consensus Rating Score
2.82
2.43
2.50
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-2.79% Downside740.67% Upside9.17% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$103.00 ➝ $112.00+15.00%
7/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $110.00+13.26%
7/10/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$92.00 ➝ $97.00-0.40%
6/24/2024BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Grundy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$109.00+12.06%
5/28/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$101.00 ➝ $103.00+12.20%
5/15/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Graja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$97.00 ➝ $107.00+13.01%
4/30/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$84.00 ➝ $85.00-6.07%
4/29/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$94.00 ➝ $95.00+4.38%
4/29/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$88.00 ➝ $95.00+4.38%
4/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$90.00 ➝ $96.00+9.44%
3/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$93.00+7.50%
1/29/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$93.00 ➝ $95.00+13.41%
1/29/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$91.00+9.86%
1/18/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$88.00 ➝ $90.00+11.55%
11/13/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$87.00+15.34%
10/12/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$82.00 ➝ $76.00+10.35%
9/22/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$84.00+14.73%
7/31/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$88.00 ➝ $91.00+20.34%
11/21/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
10/18/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$88.00 ➝ $85.00+17.83%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:25 PM ET.

CL Forecast - Frequently Asked Questions

What is Colgate-Palmolive's forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Colgate-Palmolive is $95.33, with a high forecast of $112.00 and a low forecast of $76.00.

Should I buy or sell Colgate-Palmolive stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Colgate-Palmolive in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CL shares.

Does Colgate-Palmolive's stock price have much upside?

According to analysts, Colgate-Palmolive's stock has a predicted upside of 9.16% based on their 12-month stock forecasts.

What analysts cover Colgate-Palmolive?

Colgate-Palmolive has been rated by research analysts at Argus, Bank of America, Barclays, BNP Paribas, Citigroup, Morgan Stanley, Royal Bank of Canada, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Colgate-Palmolive more than its competitors?

Analysts like Colgate-Palmolive more than other "consumer staples" companies. The consensus rating for Colgate-Palmolive is Moderate Buy while the average consensus rating for "consumer staples" companies is Hold. Learn more on how CL compares to other companies.


This page (NYSE:CL) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners